	Total (n=139)	Detected at baseline (n=104)	Detected during follow- up (n=35)	p-value
Age at diagnosis, mean ± SD	60.4 ± 11.9	60.1 ± 11.7	61.3 ± 12.6	0.608
Nodule type, n (%)				0.009
Solid	51 (36.7)	30 (28.8)	21 (60.0)	
Part-solid	47 (33.8)	41 (39.4)	6 (17.1)	
Pure GGN	34 (24.5)	27 (26.0)	7 (20.0)	
Cavitary	7 (5.0)	6 (5.8)	1 (2.9)	
Time of planning invasive diagnosis, n (%)				0.070
At first detection of relevant nodule	65 (46.8)	44 (42.3)	21 (60.0)	
During follow-up	74 (53.2)	60 (57.7)	14 (40.0)	
Time from detection to biopsy, months, mean \pm SD	19.8 ± 30.0	19.7 ± 30.0	20.2 ± 30.4	0.922
Nodule size at detection, mm, mean \pm SD	15.4 ± 8.2	16.2 ± 8.3	12.7 ± 7.7	0.029
Nodule size at biopsy, mm, mean \pm SD	17.5 ± 8.3	18.1 ± 8.2	15.7 ± 8.3	0.146
Type of biopsy, n (%)				
Video-assisted thoracic surgery (VATS)	89 (64.0)	71 (68.3)	18 (51.4)	0.073
Percutaneous needle biopsy	38 (27.3)	25 (24.0)	13 (37.1)	0.132
Bronchoscopic biopsy [*]	12 (8.6)	8 (7.7)	4 (11.4)	0.496
Diagnosed as lung cancer, n (%)	84 (60.4)	74 (71.2)	10 (28.6)	< 0.001
Diagnosed as benign (false-positive), n (%)	50 (36.0)	30 (28.8)	20 (57.1)	0.003

Supplementary Table 1. Characteristics and outcomes of biopsied nodules of neversmokers detected at baseline and during follow-up

SD=standard deviation, GGN=ground glass nodule *Including EBUS (endobronchial ultrasound) and radial-EBUS guided biopsy

Subgroups	Total	Never-smoker	Ever-smoker	p value
Age <55 (N=25,730)	25,730	11,675	14,055	
Received invasive biopsy, n/N (%)	117 (0.5)	50 (0.4)	67 (0.5)	0.565
Diagnosed as lung cancer, n/N (%)	65 (0.3)	29 (0.2)	36 (0.3)	0.902
Diagnosed as benign (false-positive), n/N (%)	52 (0.2)	21 (0.2)	31 (0.2)	0.469
Any procedure-related complication, n/N (%)	13 (0.1)	4 (0.0)	9 (0.1)	0.290
Age ≥55 (N=11,706)	11,706	6,293	5,413	
Received invasive biopsy, n/N (%)	216 (1.8)	89 (1.4)	127 (2.3)	< 0.001
Diagnosed as lung cancer, n/N (%)	142 (1.2)	55 (0.9)	87 (1.6)	< 0.001
Diagnosed as benign (false-positive), n/N (%)	67 (0.6)	29 (0.5)	38 (0.7)	0.085
Any procedure-related complication, n/N (%)	42 (0.4)	16 (0.3)	26 (0.5)	0.041
Sex: male (N=23,827)	23,827	5,644	18,183	
Received invasive biopsy, n/N (%)	226 (0.9)	42 (0.7)	184 (1.0)	0.070
Diagnosed as lung cancer, n/N (%)	136 (0.6)	20 (0.4)	116 (0.6)	0.013
Diagnosed as benign (false-positive), n/N (%)	87 (0.4)	21 (0.4)	66 (0.4)	0.921
Any procedure-related complication, n/N (%)	42 (0.2)	7 (0.1)	35 (0.2)	0.284
Sex: female (N=13,609)	13,609	12,324	1,285	
Received invasive biopsy, n/N (%)	107 (0.8)	97 (0.8)	10 (0.8)	0.973
Diagnosed as lung cancer, n/N (%)	71 (0.5)	64 (0.5)	7 (0.5)	0.904
Diagnosed as benign (false-positive), n/N (%)	32 (0.2)	29 (0.2)	3 (0.2)	0.990
Any procedure-related complication, n/N (%)	13 (0.1)	13 (0.1)	0 (0)	0.244

Supplementary Table 2. Subgroup analyses of main outcomes stratified by age and sex